MARKET

NTLA

NTLA

Intellia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

113.13
-2.39
-2.07%
Closed 16:00 11/26 EST
OPEN
112.18
PREV CLOSE
115.52
HIGH
117.95
LOW
111.01
VOLUME
494.49K
TURNOVER
--
52 WEEK HIGH
202.73
52 WEEK LOW
35.61
MARKET CAP
8.42B
P/E (TTM)
-33.6947
1D
5D
1M
3M
1Y
5Y
Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)
Approved protocol amendment enables enrollment of ATTR-CM patients in the ongoing first-in-human study of NTLA-2001, a systemically delivered...
Globe Newswire · 5d ago
Alnylam Pharma is said to be a potential target for Novartis - Bloomberg
Alnylam Pharmaceuticals (NASDAQ:ALNY) may be a potential target for Novartis as investor push for the drugmaker to make an acquisition. Alnylam, with a market cap of more than $20B could
Seekingalpha · 11/18 12:19
Ratan Capital Management LP Buys Reinvent Technology Partners Y, Mirion Technologies Inc, Bath ...
GuruFocus News · 11/16 18:38
AtonRa Partners Buys Lightspeed Commerce Inc, The Descartes Systems Group Inc, Legend Biotech ...
GuruFocus News · 11/15 21:38
BioImpact Capital LLC Buys MEI Pharma Inc, Intellia Therapeutics Inc, BioCryst Pharmaceuticals Inc
GuruFocus News · 11/15 14:40
Burrage Capital Management LLC Buys , Sells BioCryst Pharmaceuticals Inc, Intellia Therapeutics ...
GuruFocus News · 11/15 14:38
Intellia Therapeutics (NASDAQ:NTLA) shareholders have earned a 51% CAGR over the last five years
While Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) shareholders are probably generally happy, the stock hasn't had...
Simply Wall St. · 11/12 14:34
Cathie Wood's ARK Invest Posts Fund Purchases For Wednesday, Nov. 10 2021: PLTR, VCYT, MTLS, VLD, MKFG, ALLO, NTLA, VERV, TOST
Palantir (PLTR) Veracyte (VCYT) Materialise (MTLS) Velo3D (VLD) Markforged (MKFG) Allogene (ALLO) Intellia Therapeutics (NTLA) Verve Therapeutics (VERV) Toast (TOST)
Benzinga · 11/11 14:48
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NTLA. Analyze the recent business situations of Intellia through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

22.22%Strong Buy
61.11%Buy
16.67%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average NTLA stock price target is 174.56 with a high estimate of 238.00 and a low estimate of 137.00.
High238.00
Average174.56
Low137.00
Current 113.13
EPS
Actual
Estimate
-0.81-0.61-0.40-0.20
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 429
Institutional Holdings: 66.79M
% Owned: 89.75%
Shares Outstanding: 74.42M
TypeInstitutionsShares
Increased
128
5.92M
New
68
1.41M
Decreased
111
6.08M
Sold Out
40
684.03K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.30%
Pharmaceuticals & Medical Research
+0.44%
Key Executives
Non-Executive Chairman/Independent Director
Frank Verwiel
President/Chief Executive Officer/Director
John Leonard
Chief Financial Officer/Executive Vice President/Treasurer
Glenn Goddard
Executive Vice President/Chief Scientific Officer
Laura Sepp-Lorenzino
Executive Vice President/General Counsel/Secretary
James Basta
Executive Vice President
David Lebwohl
Independent Director
Frederick Cohen
Independent Director
John Crowley
Independent Director
Caroline Dorsa
Independent Director
Jean-Francois Formela
Independent Director
Jesse Goodman
Independent Director
Georgia Keresty
No Data
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing potentially curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9) technology. The Company's CRISPR/Cas9 is a technology for genome editing, process of altering selected sequences of genomic deoxyribonucleic acid (DNA). To fully realize the transformative potential of CRISPR/Cas9, the Company uses two primary approaches. The Company’s in vivo programs use intravenously administered CRISPR as the therapy, in which its delivery technology enables precise editing of disease-causing genes directly within specific target tissues. The Company’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.

Webull offers kinds of Intellia Therapeutics Inc stock information, including NASDAQ:NTLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTLA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NTLA stock methods without spending real money on the virtual paper trading platform.